Attenuation of wild-type yellow fever virus by passage in HeLa cells
- PMID: 2230735
- DOI: 10.1099/0022-1317-71-10-2301
Attenuation of wild-type yellow fever virus by passage in HeLa cells
Abstract
During the 1960s three different research groups reported that passage of wild-type yellow fever (YF) virus [strain Asibi (YF-Asibi)] in HeLa cells resulted in attenuation of the virus for monkeys so that the virus no longer caused viscerotropic disease. We have repeated and extended this observation to analyse the process of attenuation of YF virus during cell culture passage. A large plaque (LP) variant of YF-Asibi virus became attenuated for both monkeys and mice following six serial subcultures in HeLa cells (YF-Asibi-LP HeLa p6). Thus, attenuation was probably due to a genetic change in the virus population rather than to selective enrichment of a pre-existing variant of YF-Asibi-LP virus. No evidence was obtained to implicate defective interfering particles in the attenuation process. Comparison of the YF-Asibi-LP viruses before and after passage in HeLa cells, using a panel of envelope protein-reactive monoclonal antibodies (MAbs), showed that MAbs which specifically neutralize YF-Asibi-LP virus, and not YF 17D-204 vaccine virus, also neutralized YF-Asibi-LP HeLa p6. This indicated that the epitopes involved in the biological process of neutralization were not altered during attenuation. However, two MAbs that recognize envelope protein epitopes did distinguish between HeLa- and non-HeLa-passaged YF-Asibi-LP virus. One of these (MAb 117) which is YF wild-type-specific, recognized YF-Asibi-LP virus but not YF-Asibi-LP HeLa p6 virus, whereas the other (MAb411), which is YF vaccine-specific, recognized YF-Asibi-LP HeLa p6 virus but not YF-Asibi-LP virus. These results suggest that antigenic changes in the viral envelope protein may determine the relative virulence or attenuation of YF virus.
Similar articles
-
Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus.Virology. 1999 Sep 1;261(2):309-18. doi: 10.1006/viro.1999.9873. Virology. 1999. PMID: 10497116
-
Identification of envelope protein epitopes that are important in the attenuation process of wild-type yellow fever virus.J Virol. 1992 Jul;66(7):4265-70. doi: 10.1128/JVI.66.7.4265-4270.1992. J Virol. 1992. PMID: 1376368 Free PMC article.
-
Attenuation of Live-Attenuated Yellow Fever 17D Vaccine Virus Is Localized to a High-Fidelity Replication Complex.mBio. 2019 Oct 22;10(5):e02294-19. doi: 10.1128/mBio.02294-19. mBio. 2019. PMID: 31641088 Free PMC article.
-
Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein.Virology. 1983 Feb;125(1):8-17. doi: 10.1016/0042-6822(83)90059-4. Virology. 1983. PMID: 6187129
-
Use of a monoclonal antibody specific for wild-type yellow fever virus to identify a wild-type antigenic variant in 17D vaccine pools.J Gen Virol. 1989 Jul;70 ( Pt 7):1889-94. doi: 10.1099/0022-1317-70-7-1889. J Gen Virol. 1989. PMID: 2472467
Cited by
-
Adaptation of two flaviviruses results in differences in genetic heterogeneity and virus adaptability.J Gen Virol. 2007 Sep;88(Pt 9):2398-2406. doi: 10.1099/vir.0.83061-0. J Gen Virol. 2007. PMID: 17698648 Free PMC article.
-
Genome Characterization of Yellow Fever Virus Wild-Type Strain Asibi, Parent to Live-Attenuated 17D Vaccine, from Three Different Sources.Viruses. 2021 Jul 16;13(7):1383. doi: 10.3390/v13071383. Viruses. 2021. PMID: 34372589 Free PMC article.
-
Cell-specific adaptation of two flaviviruses following serial passage in mosquito cell culture.Virology. 2007 Jan 20;357(2):165-74. doi: 10.1016/j.virol.2006.08.005. Epub 2006 Sep 11. Virology. 2007. PMID: 16963095 Free PMC article.
-
Current Assessment of Yellow Fever and Yellow Fever Vaccine.Curr Infect Dis Rep. 2004 Apr;6(2):96-104. doi: 10.1007/s11908-996-0005-9. Curr Infect Dis Rep. 2004. PMID: 15023271
-
Vaccine and Wild-Type Strains of Yellow Fever Virus Engage Distinct Entry Mechanisms and Differentially Stimulate Antiviral Immune Responses.mBio. 2016 Feb 9;7(1):e01956-15. doi: 10.1128/mBio.01956-15. mBio. 2016. PMID: 26861019 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials